Switch to Etravirine from Efavirenz

SWITCH-EE STUDY
Switch from Efavirenz to Etravirine

SWITCH-EE: Design

**Study Design: SWITCH-EE**

- **Background**: Randomized, double-blind, crossover study comparing the safety and efficacy of etravirine with efavirenz

- **Inclusion Criteria (n = 58)**
  - Age ≥18 years
  - On EFV-containing ART regimen for ≥3 months
  - HIV RNA <50 copies/mL for ≥3 months

- **Treatment Arms**
  - EFV 600 mg daily + NRTI backbone x 6 weeks, then switch EFV to ETR
  - ETR 400 mg daily + NRTI backbone x 6 weeks, then switch ETR to EFV

**“EFV First” Group**

EFV 600 mg QD + NRTIs, then switch EFV to ETR
(n = 28)

**“ETR First” Group**

ETR 400 mg QD + NRTIs, then switch ETR to EFV
(n = 30)

Switch from Efavirenz to Etravirine

SWITCH-EE: Result

Week 12: Treatment Preference

Switch from Efavirenz to Etravirine
SWITCH-EE: Result

Week 12: Treatment Preference, with Significant Order Effect

Switch from Efavirenz to Etravirine

SWITCH-EE: Result

Week 12: Change in Plasma Lipids from Baseline

<table>
<thead>
<tr>
<th>Lipid</th>
<th>End of Efavirenz Period</th>
<th>End of Etravirine Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol</td>
<td>5.5</td>
<td>4.6</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>1.7</td>
<td>1.4</td>
</tr>
<tr>
<td>HDL</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>LDL</td>
<td>3.3</td>
<td>2.8</td>
</tr>
</tbody>
</table>

Conclusion: “After substitution of efavirenz by etravirine, patients did not express a significant preference for etravirine. There was no measurable effect on neuropsychiatric symptoms and sleep. Cholesterol decreased.”
The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.